secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2026-05-29T20:05:43+00:00
Accession:  0001683168-26-004387
Event type: other_material
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Majority shareholder approves >20% stock issuance at discount; warrant adjustments allowed
--------------------------------------------------------------------------------

- CEO Dr. Steve N. Slilaty, holding ~86% voting power, approved issuance of >20% of outstanding shares at discount to Nasdaq min price.
- Consent allows adjustment of Series C Warrants' exercise price or shares in a Share Combination Event.
- Consent allows voluntary adjustment of Series C Warrant exercise prices from time to time.
- Consent effective 20 days after mailing definitive info statement; part of May 19, 2026 public offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826004387/0001683168-26-004387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826004387/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-004387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer